Navigation Links
Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
Date:9/26/2007

BETHESDA, Md., Sept. 26 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum in Zurich, Switzerland on Tuesday, October 2, 2007 at 12:00 noon central European time (6:00 am Eastern time).

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases. Three product candidates are currently in clinical trials. MT103, also known as MEDI-538, is the first product candidate based on Micromet's novel BiTE(R) antibody product development platform and is being evaluated in a phase 1 clinical trial for the treatment of patients with non- Hodgkin's lymphoma. The BiTE antibody product development platform is based on a unique, antibody-based class of drugs that leverages the cytotoxic potential of T cells in the treatment of cancer. T cells are the most powerful 'killer cells' of the human immune system. Micromet has established a collaboration with MedImmune, Inc. for MT103/MEDI-538. The second clinical stage product candidate is adecatumumab, also known as MT201, a recombinant human monoclonal antibody which targets EpCAM expressing tumors. Adecatumumab is being developed for the treatment of patients with breast cancer. A phase 2a clinical trial in this indication has been complete
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...wire-FirstCall/ - Microbix Biosystems Inc. (the "C...Form 52-109F1 Certification of Annual Filings of W...es Long, the Chief Financial Officer (the "Officer...tion with the annual audited financial statements ...ompany initially filed the annual financial statem...
(Date:11/6/2009)... Helix BioPharma Corp. (...ced that John Docherty, president and chief operat...s 6th annual Investor Summit on November 10, 2009 ... Mr. Docherty will provide an overview of the Comp... and Topical Interferon Alpha-2b. The slide show ...
(Date:11/6/2009)...vember 6 EUCODIS Bioscience, a com...arketing enzymes for the,chemical industry announc...ment with Bio Sidus, the leading biopharmaceutical...t gives EUCODIS Bioscience exclusive access - for ...proprietary collection of,psychrophilic bacteria s...
(Date:11/6/2009)...Nov. 6 Calbiotech, Inc. announced ...novative Research (SBIR) Phase I contract by the U...der terms of the agreement, Calbiotech will develo...is of Dengue virus. ,, Dengue virus is a mos...at to military forces deployed to tropical areas o...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2
...d., March 16 Micromet, Inc. (Nasdaq: MITI ), a ...etary antibodies for the treatment of cancer, infl...the publication of six abstracts for poster presen... place from April 20-24, 2009, in Denver, Colorado... , , , Lutterbuese, R. et al. (2009). H...
...ch 16 PAREXEL experts will address the benefits o... 110th Annual Meeting of the American Society for ... be held at the Gaylord National Resort in Nationa...ocus of PAREXEL,s presence at the ASCPT meeting wi...nd best practice approaches for identifying and se...
...ng expenses decreased by 33% in 2008; Forecast cut...n 2009 , , CTI expects to complete pixantrone ND...ell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC...ial results for the fourth quarter and year ended ... Met primary endpoint in the Phase III study ...
Other Biology Technology:Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 2Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 3Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 4Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 5PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 2PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 3PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting 4Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 2Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 3Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 4Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 5Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 6Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 7Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 8
(Date:11/9/2009)...O, Calif., Nov. 9 Genencor, a divi... Energy Award" from the American Institute of Chem...amily of enzymes for cellulosic ethanol. Yesterday...e, presented the award to Landon Steele, who is Ma...#174; Product Manager, and Aaron Kelley, who is Se...
(Date:11/9/2009)... culprit responsible for the rapid, mysterious dea...s been found by collaborating scientists at Rutger...itution (WHOI). This same chemical may hold unexp...covered a previously unknown lipid, or fatty compo...g Emiliania huxleyi , a phytoplankton that plays ...
(Date:11/9/2009)..., NOVEMBER 9, 2009 A nutritionist whose research...to the federal Women, Infants and Children (WIC) f...Higgins Award for outstanding achievement in the f...son, Ph.D., MNS, , a professor in the Department o...alifornia, Los Angeles School of Public Health, wi...
Breaking Biology News(10 mins):Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2SEI Defined Benefit Client Recognized With Leading Plan Design Award 5454 1SEI Defined Benefit Client Recognized With Leading Plan Design Award 5454 2DuraHeart 26amp 3B 238482 3B Third Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio th 59434 1DuraHeart 26amp 3B 238482 3B Third Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio th 59434 2DuraHeart 26amp 3B 238482 3B Third Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio th 59434 3Dr Floyd Bloom Joins aTyr Pharmas Scientific Advisory Board 14466 1Dr Floyd Bloom Joins aTyr Pharmas Scientific Advisory Board 14466 2Dr Floyd Bloom Joins aTyr Pharmas Scientific Advisory Board 14466 3
...he primary targets of HIV-1 infection in the human... study published in the February 2007 issue of the...ndings are likely to guide development of new stra...he majority of HIV-1 infected individuals worldwid...xual contact," explain study authors Dr. Florian H...
...n his Jan. 23 State of the Union address, Presiden...on,s dependency on foreign oil by requiring the pr... and alternative fuels by 2017, roughly five times... gallons by 2012. , Among the most promising alter.... Currently, the main biofuel used in the United S...
...n his Jan. 23 State of the Union address, Presiden...on,s dependency on foreign oil by requiring the pr... and alternative fuels by 2017, roughly five times... gallons by 2012. , Among the most promising alter.... Currently, the main biofuel used in the United S...
Other Biology News:Researchers discover new details about HIV-1 entry and infection 2Custom-made cancer cell attacks 2Custom-made cancer cell attacks 3Cellulosic ethanol: Fuel of the future? 2Cellulosic ethanol: Fuel of the future? 3
Mouse Anti-Human FACTOR I Monoclonal Antibody, Unconjugated, Clone 3R2/2 from AbD Serotec
Human, Bovine, Porcine, Rat VIP, aa 6-28 from Biotrend Chemikalien GmbH
RAPTOR from Bioinformatics Solutions Inc.
Mouse Anti-L1 Protein of Human Papilloma Virus Monoclonal Antibody, Unconjugated, Clone CAMVIR-1 from BD Biosciences Pharmingen
Biology Products: